Compare Edgewise Therapeutics Inc. Common Stock (EWTX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edgewise Therapeutics Inc. Common Stock vs ProShares UltraPro S&P500 — how do they compare? Edgewise Therapeutics Inc. Common Stock trades at $37.04 (market cap $3.94B), while ProShares UltraPro S&P500 trades at $148.91 (market cap $5.68B). The key difference: ProShares UltraPro S&P500 is the larger of the two by market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Edgewise Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Edgewise Therapeutics Inc. Common Stock for 0 Days and ProShares UltraPro S&P500 for 30 Days on average.
| EWTX | UPRO | |
|---|---|---|
Market Cap | $3.94B | $5.68B |
Volume | 810,104 | 1,616,348 |
Sector | Health | Leveraged / Inverse |
52-Week High | $48.35 | $157.66 |
52-Week Low | $14.89 | $89.29 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $3.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
UPRO trades at $155.38, showing minimal daily movement with a slight 0.05% decline. The technical outlook remains bullish with strong moving average signals, though oscillators indicate neutral momentum. Recent news highlights S&P 500 valuation concerns and expected profit growth deceleration from 35% in 2026 to 15% in 2027, creating mixed sentiment for this leveraged ETF.
As a leveraged S&P 500 ETF, UPRO's performance is tied to broader market movements. Current technical strength supports near-term upside potential, but elevated RSI levels and slowing earnings growth projections for the underlying index present headwinds. The ETF's leveraged structure amplifies both gains and losses, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Edgewise Therapeutics Inc. Common Stock
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies based on its research in muscle physiology, with a pipeline focused on cardiovascular and cardiometabolic conditions such as hypertrophic cardiomyopathy and heart failure.
Read more on EWTX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
